

May 6, 2019



# DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019

MINNEAPOLIS, May 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on Monday, May 13<sup>th</sup>. DiaMedica's management will host a live conference call on Tuesday, May 14<sup>th</sup> at 7:00am Central Time to provide a business update and discuss the Company's financial results.

## Conference Call details:

|                |   |
|----------------|---|
| Date:          | Tuesday, May 14, 2019   |
| Time:          | 7:00 AM CT  |
| Web access:    | <a href="https://edge.media-server.com/m6/p/qrb8q6a5">https://edge.media-server.com/m6/p/qrb8q6a5</a> |
| Dial In:       | (866) 962-3583 (domestic)<br>(630) 652-5857 (international)   |
| Conference ID: | 8177137   |

Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 21, 2019, by dialing 1(855) 859-2056 (US Toll Free Dial In), (404) 537-3406 (international), replay passcode 8177137.

## ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

For more information, please visit [www.diamedica.com](http://www.diamedica.com) or follow us on [Twitter](#).

## **Contact:**

Scott Kellen  
Chief Financial Officer  
Phone: (763) 496-5118  
[skellen@diamedica.com](mailto:skellen@diamedica.com)

Paul Papi  
Vice President of Business Development

Phone: (617) 899-5941  
[info@diamedica.com](mailto:info@diamedica.com)



Source: DiaMedica Therapeutics Inc.